Avantor Announces Secondary Offering of 38,500,000 Shares of Common Stock

8/20/20

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission critical products and services to customers in the life sciences and advanced technologies & applied materials industries, today announced that certain of its stockholders, including an affiliate of New Mountain Capital, LLC, intend to offer for sale in an underwritten secondary offering 38,500,000 shares of common stock of the Company pursuant to a registration statement filed by the Company with the U.S. Securities and Exchange Commission. The Selling Stockholders expect to grant the underwriters a 30-day option to purchase up to an additional 5,775,000 shares of common stock on the same terms and conditions. No shares are being sold by the Company. The Selling Stockholders will receive all of the proceeds from this offering.

Goldman Sachs & Co. LLC and J.P. Morgan are acting as the underwriters for the proposed offering.

A registration statement relating to these securities has been filed with the SEC and has become effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Avantor
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. One of our greatest strengths comes from having a global infrastructure that is strategically located to support the needs of our customers. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world.

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.